Publications by authors named "W E Rote"
Article Synopsis
- The phase 3 DUPLEX trial is testing sparsentan, a new medication for patients with focal segmental glomerulosclerosis (FSGS), focusing on its safety and effectiveness.
- This global study involves 371 patients aged 8 to 75, comparing sparsentan 800 mg to irbesartan 300 mg, while analyzing their baseline characteristics related to FSGS severity.
- As the largest interventional study of its kind, DUPLEX aims to provide valuable insights into sparsentan's treatment effects across a diverse, worldwide patient population.
Article Synopsis
- The PROTECT trial, a phase 3 study, evaluated the effectiveness of sparsentan, a dual receptor antagonist, in reducing proteinuria compared to irbesartan in patients with immunoglobulin A nephropathy over 110 weeks.* -
- A total of 406 patients were randomly assigned to either sparsentan or irbesartan, with the primary goal being the change in proteinuria at 36 weeks and secondary goals related to kidney function and safety over the trial duration.* -
- The findings from the trial, which included a significant reduction in proteinuria with sparsentan, provide important insights into potential treatment strategies for patients with kidney conditions.*
Article Synopsis
- - A phase 3 trial investigated the long-term effects of sparsentan versus irbesartan in treating focal segmental glomerulosclerosis (FSGS) over 108 weeks, enrolling 371 patients aged 8 to 75.
- - At 36 weeks, sparsentan showed a significantly higher rate of partial remission of proteinuria (42%) compared to irbesartan (26%), and this positive response continued up to 108 weeks.
- - However, there were no significant differences in the estimated glomerular filtration rate (eGFR) slopes between the two groups at the final analysis, indicating that while proteinuria improved, kidney function as measured by eGFR remained similar with both treatments. *
The COVID-19 pandemic and subsequent stay-at-home orders limited adolescents' ability to connect with friends in person, leading adolescents to rely on digital forms of communication to interact with friends. The present study ( = 168 adolescents ages 11-20, 51.40% female) examined the types of digital communication adolescents used to connect with friends during the pandemic stay-at-home orders and how each form of digital communication related to adolescents' emotional adjustment.
View Article and Find Full Text PDFArticle Synopsis
- Sparsentan is a new type of medication being tested in the ongoing PROTECT trial for adults with IgA nephropathy (IgAN), with potential benefits in reducing inflammation and improving blood flow, without suppressing the immune system.
- The PROTECT trial is a large, international study comparing the effectiveness and safety of sparsentan against the active drug irbesartan in patients with significant proteinuria who have not found success with previous treatments.
- Results from 404 enrolled patients showed a mix of demographics and health statuses, which will help understand how sparsentan works across different populations and stages of chronic kidney disease (CKD).